8-K

                                  UNITED STATES
                       SECURITIES AND EXCHANGE COMMISSION
                              Washington, DC 20549

                                    FORM 8-K


                             CURRENT REPORT Pursuant
                          to Section 13 or 15(d) of the
                         Securities Exchange Act of 1934

     Date of report (Date of earliest event reported):  September 14, 2004


                           Integrated BioPharma, Inc.
             (Exact Name of Registrant as Specified in Its Charter)

                                    Delaware
                 (State or Other Jurisdiction of Incorporation)

          000-28876                                   22-2407475
  (Commission File Number)                  (IRS Employer Identification No.)

                225 Long Avenue
          Hillside, New Jersey 07205
  (Address of Principal Executive Offices)              (Zip Code)

                                 (973) 926-0816
              (Registrant's Telephone Number, Including Area Code)


          (Former Name or Former Address, if Changed Since Last Report)

     Check the appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligation of the registrant under any of the
following provisions (see General Instruction A.2. below):

     |_| Written communications pursuant to Rule 425 under the Securities Act
         (17 CFR 230.425)

     |_| Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17
         CFR 240.14a-12)

     |_| Pre-commencement communications pursuant to Rule 14d-2(b) under the
         Exchange Act (17 CFR 240.14d-2(b))

     |_| Pre-commencement communications pursuant to Rule 13e-4(c) under the
         Exchange Act (17 CFR 240.13e-4(c))




Item 7.01. Regulation FD Disclosure

              On September 14, 2004, Integrated  BioPharma, Inc., a Delaware
corporation (the "Company"),  issued a press release  stating  that NuCycle
Therapy, Inc., INB's wholly owned subsidiary, has formed a Scientific Advisory
Board (SAB). The press release is attached as an exhibit to this Report.


Item 9.01. Financial Statements and Exhibits

(c) Exhibits.

Exhibit No.   Description
99.1          Press Release issued by Integrated BioPharma, Inc. on
              September 14, 2004.

                                       1




                                   SIGNATURES

         Pursuant to the requirements of the Securities Exchange Act of 1934,
the Registrant has duly caused this Report to be signed on its behalf by the
undersigned thereunto duly authorized.

                                  INTEGRATED BIOPHARMA, INC.


Date:  September 14, 2004         By: /s/ Eric Friedman
                                  Eric Friedman
                                  Vice President and Chief Financial Officer

EX-99

                                                                    Exhibit 99.1

NEWS RELEASE for September 14, 2004
Contact: Brian Kennedy                      Eric Friedman, CFO
         Allen & Caron Inc                  Integrated BioPharma Inc
         212 691 8087                       888 319 6962
         brian@allencaron.com               e.friedman@chemintl.com

             NUCYCLE THERAPY, INC. FORMS A SCIENTIFIC ADVISORY BOARD

HILLSIDE, NJ (September 14, 2004) Integrated BioPharma Inc (Amex: INB) is
pleased to announce that NuCycle Therapy, Inc., INB's wholly owned subsidiary,
has formed a Scientific Advisory Board (SAB), that consists of medical doctors
and professionals with multidisciplinary talents. The purpose of the SAB is to
provide NuCycle with guidance on the development and application of its
plant-produced human therapeutic proteins and vaccines.

     Integrated BioPharma Chairman and CEO, E. Gerald Kay said, "This
prestigious group of individuals will provide NuCycle with the guidance needed
to create a new production platform for human therapeutics and vaccines. Because
of its patented technology, NuCycle is in a unique position to change the manner
in which vaccines are produced."

     The Scientific Advisory Board consists of the following members, indicated
in alphabetical order:

     Orn Adalsteinsson, Ph.D., President of NuCycle Therapy, Inc. Dr.
Adalsteinsson has held several executive positions in the life science industry
during his 25-year career. As former President of DCV Biologics LP, a joint
venture between DuPont and Conagra, he developed nationally distributed
nutraceutical products. Dr. Adalsteinsson has held numerous managerial positions
during his tenure at DuPont and Procter & Gamble.

     Burt Ensley, Ph.D. is the former President and Vice President of Research
of NuCycle Therapy, Inc. Dr. Ensley has directed research, field demonstrations
and evaluation of biological and related physical/chemical technologies
applicable to the treatment of hazardous wastes. He was a research manager at
Amgen, Inc. where he developed methods and applications for the genetic
engineering of metabolic operons. Dr. Ensley holds numerous patents.

     Reinhard Gluck, PhD., Chief Scientific Officer and Member of the Executive
Board of Directors of Berna Biotech Ltd (formerly Swiss Serum & Vaccine
Institute).



Dr. Gluck is world renowned for his expertise in vaccine development and
production, and he has been responsible for major vaccine products that are sold
worldwide.

     Adalsteinn Gudmundsson, MD, Medical Chief of Hrafnista, the largest chain
of nursing homes in Iceland. Dr. Gudmundsson is actively involved in several
human research projects, including an ongoing 30 million dollar geriatric study.
Dr. Gudmundsson holds a clinical assistant professor position at the University
of Wisconsin, Madison.

     William F. Hartman, Ph.D., Vice President of Fraunhofer USA. Dr. Hartman,
former Johns Hopkins University professor of mechanics and materials science,
has over twenty-five years of executive experience in the development and
management of technological businesses. He has served as a director of five
technology companies, including two start-up companies. He is responsible for
the strategic growth and management of the non-profit organization, Fraunhofer
USA, that runs five technology centers throughout the United States.

     Michel Klein, MD, Chief Executive Officer, CANVAC, Canadian Network for
Vaccines and Immunotherapeutics. He has held the position of professor of
immunology at the University of Toronto, and he is the former Vice President of
Science and Technology, Aventis Pasteur Group. Dr. Klein has led a large team of
scientists developing major vaccine products, some of which are being marketed
worldwide.

     Martin Lipkin, MD, Professor of Medicine, Weill Medical College of Cornell
University, Director of Clinical Research Strang Cancer Prevention Center -
Strang Cancer Research Laboratory at Rockefeller University, New York City. Dr.
Lipkin is head of a group of investigators who have developed one of the largest
collections of mouse models used in pre-clinical studies for cancer prevention
and cancer treatment trials.

     Zivko L. Nikolov, Ph.D., Dow Chemical Professor at Texas A&M University. He
is the former Vice President of Bioprocess Development and Production at
Prodigene Inc. Dr. Nikolov is a known authority in bioprocessing of transgenic
plants, purification development and scale-up of plant-produced therapeutic
proteins and vaccines.

     Michael Pariza, Ph.D., Director of the Food Research Institute (FRI),
Wisconsin Distinguished Professor, and Chair of the Department of Food
Microbiology and Toxicology, University of Wisconsin, Madison. Dr. Pariza holds
numerous patents, including several in the area of conjugated linoleic acids
(CLA), which have resulted in major nutraceutical products in Europe and in the
United States. Dr. Pariza is a world authority on food safety and has testified
on food safety issues in front of the United States Congress.



     Dean Stull, Ph.D., President of Paxis Pharmaceuticals, Inc. Dr. Stull has
served in executive positions and founded several companies in the areas of
pharmaceutical and chemical technologies. He has served on several for-profit
and non-profit boards including the Colorado Institute for Research in
Biotechnology and the Governors Committee on High Technology. Dr. Stull has
facilitated commercialization of technologies related to the pharmaceutical,
food and dietary supplement industries.

     Vidadi Yusibov, Ph.D., Chief Scientific Director of Fraunhofer USA, Center
for Molecular Biotechnology. Dr. Yusibov holds numerous patents and leads a
sizeable group of scientists in carrying out some of the pioneering programs of
plant-produced human therapeutic proteins and vaccines.

     Karl Zimmerman, MD, Practicing Internist in Unionville, Pennsylvania.
Dr. Zimmerman runs a large private practice in the southern part of Pennsylvania
and is a leading innovator in the application/development of nutraceuticals for
use along with conventional pharmaceutical therapies.

About Integrated BioPharma Inc (INB)
     INB serves the pharmaceutical, biotech and nutraceutical industries.
Through several wholly owned subsidiaries, INB develops, manufactures and
distributes more than 130 products worldwide. Its subsidiary, Paxis
Pharmaceuticals, Inc., develops and operates a state-of-the-art GMP facility for
the production and sale of paclitaxel and related drugs. Through its biotech
subsidiary, NuCycle Therapy, Inc., INB is developing human therapeutics and
preventive cancer compounds in transgenic plants. Further information is
available at www.iBioPharma.com.

     Statements included in this release may constitute forward-looking
statements within the meaning of the Private Securities Litigation Reform Act of
1995. Such statements involve a number of risks and uncertainties such as
competitive factors, technological development, market demand, and the company's
ability to obtain new contracts and accurately estimate net revenues due to
variability in size, scope and duration of projects, and internal issues in the
sponsoring client. Further information on potential risk factors that could
affect the company's financial results can be found in the company's Reports
filed with the Securities and Exchange Commission.